Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Swing Factors” Will Heavily Influence GSK Growth In ’08, Chief Exec Garnier Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Outcome of a plan to jumpstart sales of Avandia and FDA approval of Cervarix are two key issues that will impact GSK in the new year.

You may also be interested in...



GSK Will Answer FDA “Complete Response” Letter For Cervarix In Second Quarter

Advisory committee review of the human papilloma virus vaccine expected, CEO Garnier says during year-end earnings call.

GSK Will Answer FDA “Complete Response” Letter For Cervarix In Second Quarter

Advisory committee review of the human papilloma virus vaccine expected, CEO Garnier says during year-end earnings call.

GSK Receives “Complete Response” Letter For Cervarix BLA

Drug maker will respond to FDA “as soon as possible” to answer outstanding questions related to the HPV vaccine.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel